| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2016: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
Control of the recurrence of distant metastases after surgery is a major problem for improvement of prognosis after resection of primary lung cancer. There are not many cases where relapse or distant metastasis still occurs even if tumor can be completely resected. The involvement of circulating tumor cells in the blood is suggested for tumor hematogenous metastasis. We have quantitated the CTC of peripheral blood and pulmonary venous blood of lung cancer patients and found association with distant metastasis.
In this study, we aimed to find a new target for lung cancer treatment by trying to isolate lung cancer cells having proliferation and engraftment ability from the blood of the pulmonary vein leading from the lung to the general circulation, but this time in the lung cancer patients who were performed surgery, it is rarely seen that cancer cells in the pulmonary vein blood with self-proliferating ability outside the body.
|
